Davis Polk is advising J.P. Morgan Securities LLC as financial adviser to LabCorp in connection with its approximately $1.2 billion acquisition of Chiltern International Ltd. The transaction, which is expected to close in the fourth quarter of 2017, is subject to regulatory approvals and customary closing conditions.

LabCorp is a global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. Chiltern, a global contract research organization, is a provider of clinical services and solutions in a variety of therapeutic areas with engagement models for biopharmaceutical and medical device industries.

The Davis Polk corporate team includes partner Phillip R. Mills and associate Arthi Sridharan. All members of the Davis Polk team are based in the New York office.

Copy link to share post